Benchmark against your competition
Understand how AI crawlers access your site
See where AI gets info about you
Track the queries mentioning your brand
Own your AI narrative
Add GEO to your service offerings
Get recommended in shopping queries
Monitor AI mentions at scale
Theravance Biopharma US, LLC
What AI says about Theravance Biopharma US, LLC
Theravance Biopharma focuses on developing innovative medicines for patients with serious respiratory and neurologic conditions. Their lead product, YUPELRI® (revefenacin), is an FDA-approved inhalation solution for chronic obstructive pulmonary disease (COPD).
Is this your brand?
Claim this profile to keep your information accurate and add what's missing.
Not in this profile yet:
Products & Services
YUPELRI® (revefenacin) Inhalation Solution
An FDA-approved inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Ampreloxetine
A late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.
Common Questions
What is YUPELRI® used for?
YUPELRI® is used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
What is Ampreloxetine?
Ampreloxetine is an investigational drug being developed for treating symptomatic neurogenic orthostatic hypotension.
Who does Theravance Biopharma serve?
Theravance Biopharma serves patients with specialty respiratory and neurologic diseases.
What is the company's mission?
Theravance Biopharma's mission is to deliver Medicines that Make a Difference in people's lives.
How does Theravance Biopharma approach drug development?
Theravance Biopharma leverages decades of expertise and focuses on insight and innovation to develop new therapies.